Compare LILAK & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LILAK | NUVB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2017 | 2020 |
| Metric | LILAK | NUVB |
|---|---|---|
| Price | $9.81 | $4.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $8.20 | ★ $12.45 |
| AVG Volume (30 Days) | 1.7M | ★ 4.9M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.55 | ★ 71.56 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,442,200,000.00 | $62,902,000.00 |
| Revenue This Year | $0.60 | $222.99 |
| Revenue Next Year | $3.23 | $23.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $4.75 | $3.98 |
| 52 Week High | $10.42 | $9.75 |
| Indicator | LILAK | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 67.41 | 32.21 |
| Support Level | $7.44 | N/A |
| Resistance Level | N/A | $5.06 |
| Average True Range (ATR) | 0.48 | 0.26 |
| MACD | 0.18 | -0.02 |
| Stochastic Oscillator | 76.79 | 3.87 |
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.